DermaFlow peripheral blood flow technology has many clinical applications, either as a stand-alone system, or embedded in vital sign monitoring suites. The technology has been applied to one consumer-oriented product, with discussions ongoing for a second.
Financial return is the reward for all successful investments. DermaFlow is seeking investment to scale up manufacture and expand clinical trials, regulatory and marketing efforts for a proprietary technology that has a recognized consumer healthcare and clinical need. The company has a comprehensive Due Diligence package to share with potential investors that will provide full details on all aspects of the company’s operations and projections, and will highlight the financial opportunities for investment in DermaFlow.
With the first products nearing completion, DermaFlow is being transformed from an R&D start-up to a commercial venture. The company will produce a regular newsletter which will feature news and events and milestones achieved in the pathway towards success.